Zhaoke Ophthalmology Pharmaceutical

About Zhaoke Ophthalmology Pharmaceutical

Zhaoke Ophthalmology Limited is a pharmaceutical company headquartered in Guangzhou, China, that specializes in the research, development, manufacturing, and commercialization of treatments for eye diseases. Founded in January 2017, the company was spun-off from its parent company, Lee's Pharmaceutical Holdings Limited. The company's Chairman and CEO is Dr. Li Xiaoyi, who founded Lee's Pharm in 1994 and has over 25 years of experience in pharmaceutical research and development.

Zhaoke Ophthalmology went public on the Hong Kong Stock Exchange (SEHK: 6622) on April 29, 2021, raising approximately $267 million. The initial public offering attracted cornerstone investors such as GIC, Hillhouse Capital, and TPG. The business model focuses on developing and commercializing a comprehensive portfolio of both innovative and generic ophthalmic drugs, targeting unmet medical needs primarily in Greater China, while also expanding into other markets like South Korea, Australia, New Zealand, and the Middle East through strategic partnerships. The company generates revenue through drug sales and licensing income.

The firm has a pipeline of over 25 drug candidates targeting the six major ophthalmic indications: dry eye disease (DED), myopia, presbyopia, wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and glaucoma. Flagship assets include NVK002, a low-concentration atropine formulation for myopia progression in children; CsA Ophthalmic Gel for DED; and TAB014 for wAMD. The company operates a cGMP-compliant manufacturing facility in Nansha, Guangzhou, to support its production needs. Zhaoke Ophthalmology also collaborates with international partners, such as Visus Therapeutics and IACTA, to co-develop and license new therapies.